There is urgent need for the development of mechanistically different and less side-effect
prone antipsychotic compounds. The endocannabinoid system has been suggested to …

Schizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental
disorders that cause high levels of functional disabilities. Also, the currently available …

Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment,
including learning, memory and attention deficits. Antipsychotic drugs are limited in their …

Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa, has been
reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects. We …

Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its
pharmacotherapy remains problematic without recent major advances. The development of …

Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and
economic strain on the individual and society-at-large. Unfortunately, currently available …

Schizophrenia (SCZ) treatment is essentially limited to the use of typical or atypical
antipsychotic drugs, which suppress the main symptoms of this mental disorder. Metabolic …

Clinical and neurobiological findings suggest that the cannabinoids and the
endocannabinoid system may be implicated in the pathophysiology and treatment of …

Deficits in an operational measure of sensorimotor gating–the prepulse inhibition of startle
(PPI)–are presented in psychiatric disorders such as schizophrenia, bipolar disorder, and …

Many symptoms used routinely for human psychiatric diagnosis cannot be directly observed
in animals which cannot describe their internal states. However, the ultrasonic vocalizations …